Disc Medicine, Inc. Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Disc Medicine, Inc. (IRON) had Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount of $51.87 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Additional Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions · last filed 2024-11-12
- 2024-09-30: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $51.87M.
- 2024-06-30: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $50.59M.
- 2024-03-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $53.35M.
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount $11.50M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount |
|---|---|
| 2024-09-30 | $51.87M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $50.59M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $53.35M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $11.50M 10-K · filed 2024-03-21 |
| 2023-09-30 | $11.10M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $10.50M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $9.30M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $10.00M 10-K · filed 2023-03-31 |
| 2021-12-31 | $24.70M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |